Lagendijk M, Vos E L, Koning A H J, Hunink M G M, Pignol J P, Corten E M L, de Monye C, van Deurzen C H M, van Dam J H, Vrijland W W, Contant C M E, Verhoef C, van Lankeren W, Koppert L B
Department of Oncological Surgery, Erasmus MC Cancer Institute, DHA-102, PO Box 5201, 3008, AE Rotterdam, The Netherlands.
Department of Bioinformatics, Erasmus MC, Rotterdam, the Netherlands.
BMC Cancer. 2017 May 17;17(1):336. doi: 10.1186/s12885-017-3280-y.
Cosmetic result following breast conserving surgery (BCS) for cancer influences quality of life and psychosocial functioning in breast cancer patients. A preoperative prediction of expected cosmetic result following BCS is not (yet) standard clinical practice and therefore the choice for either mastectomy or BCS is still subjective. Recently, we showed that tumour volume to breast volume ratio as well as tumour location in the breast are independent predictors of superior cosmetic result following BCS. Implementation of a prediction model including both factors, has not been studied in a prospective manner. This study aims to improve cosmetic outcome by implementation of a prediction model in the treatment decision making for breast cancer patients opting for BCS.
METHODS/DESIGN: Multicentre, single-blinded, randomized controlled trial comparing standard preoperative work-up to a preoperative work-up with addition of the prediction model. Tumour volume to breast volume ratio and tumour location in the breast will be used to predict cosmetic outcome in invasive breast cancer patients opting for BCS. Three dimensional (3D)-ultrasonography will be used to measure the tumour volume to breast volume ratio needed for the prediction model. Sample size was estimated based on a 14% improvement in incidence of superior cosmetic result one year after BCS (71% in the control group versus 85% in the intervention group). Primarily cosmetic outcome will be evaluated by a 6-member independent panel. Secondary endpoints include; (1) patient reported outcome measured by BREAST-Q, EORTC-QLQ-C30/BR23 and EQ-5D-5 L (2) cosmetic outcome as assessed through the BCCT.core software, (3) radiation-induced reaction (4) surgical treatment performed, (5) pathological result and (6) cost-effectiveness. Follow-up data will be collected for 3 years after surgery or finishing radiotherapy.
This randomized controlled trial examines the value of a preoperative prediction model for the treatment-decision making. It aims for a superior cosmetic result in breast cancer patients opting for BCS. We expect improvement of patients' quality of life and psychosocial functioning in a cost-effective way.
Prospectively registered, February 17th 2015, at 'Nederlands Trialregister - NTR4997 '.
乳腺癌保乳手术(BCS)后的美容效果会影响乳腺癌患者的生活质量和心理社会功能。术前预测BCS后的预期美容效果目前尚未成为标准临床实践,因此乳房切除术或BCS的选择仍然具有主观性。最近,我们发现肿瘤体积与乳房体积之比以及肿瘤在乳房中的位置是BCS后美容效果较好的独立预测因素。尚未对包含这两个因素的预测模型进行前瞻性研究。本研究旨在通过在选择BCS的乳腺癌患者的治疗决策中应用预测模型来改善美容效果。
方法/设计:多中心、单盲、随机对照试验,比较标准术前检查与添加预测模型后的术前检查。肿瘤体积与乳房体积之比以及肿瘤在乳房中的位置将用于预测选择BCS的浸润性乳腺癌患者的美容效果。三维(3D)超声检查将用于测量预测模型所需的肿瘤体积与乳房体积之比。样本量是根据BCS术后一年美容效果较好的发生率提高14%来估计的(对照组为71%,干预组为85%)。主要美容效果将由一个6人独立小组进行评估。次要终点包括:(1)通过BREAST-Q、EORTC-QLQ-C30/BR23和EQ-5D-5L测量的患者报告结局;(2)通过BCCT.core软件评估的美容效果;(3)放射诱导反应;(4)实施的手术治疗;(5)病理结果;(6)成本效益。术后或放疗结束后将收集3年的随访数据。
这项随机对照试验检验了术前预测模型在治疗决策中的价值。其目标是使选择BCS的乳腺癌患者获得更好的美容效果。我们期望以具有成本效益的方式改善患者的生活质量和心理社会功能。
前瞻性注册于2015年2月17日,在“荷兰试验注册中心 - NTR4997”。